S-1: Kairos Pharma Seeks to Raise $15 Million Through Stock Resale by Helena Global Investment Opportunities

Kairos Pharma is registering shares for resale by Helena Global Investment Opportunities I Ltd., potentially raising up to $15 million through an equity line of credit agreement.

Summary

• Kairos Pharma has filed a registration statement for the resale of its common stock by Helena Global Investment Opportunities I Ltd.
• The offering includes up to $15 million worth of shares issuable under an equity line of credit agreement (ELOC) and 670,641 shares already held by Helena.
• Kairos may receive up to $15 million in gross proceeds from Helena under the ELOC Agreement, but the actual amount may be less depending on the number of shares sold and the price.
• The purchase price per share for Helena will be 95% of the lowest intraday sale price during the three trading days preceding the purchase.
• The company intends to use the net proceeds from the ELOC Agreement to fund clinical trials, potential acquisitions, and for working capital.
• The resale of a significant quantity of shares could cause the market price of Kairos' common stock to decline and be highly volatile.
• As of April 18, 2025, there were 16,693,306 shares of common stock outstanding.
• If all 16,295,641 shares offered for resale were issued and outstanding, they would represent approximately 49.4% of the total number of shares outstanding.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights potential funding through the ELOC agreement and ongoing clinical trials, it also acknowledges risks related to dilution, market volatility, and dependence on a single funding source. The company's focus on addressing unmet needs in cancer treatment is positive, but the challenges and uncertainties associated with drug development temper the overall outlook.

Positives

• The ELOC Agreement provides Kairos Pharma with a potential source of funding for clinical trials and other corporate purposes.
• The company has the discretion to determine the timing and amount of sales to Helena under the ELOC Agreement.
• The company intends to use the proceeds from the sale of common stock under the ELOC Agreement, if any, for working capital and general corporate purposes, which includes funding our ongoing clinical trials, capital expenditures and working capital.

Negatives

• The resale of shares by Helena could cause the market price of Kairos' common stock to decline and be highly volatile.
• The purchase price for shares sold to Helena will be less than the prevailing market price.
• Existing stockholders will experience dilution as a result of the issuance of shares to Helena.
• The company may use the proceeds from the ELOC Agreement in ways that do not yield a significant return.
• The company may not have access to the full amount available under the ELOC Agreement.

Risks

• The company may not be able to sell all of the shares registered under the ELOC Agreement.
• The market price of the company's common stock could decline due to the resale of shares by Helena.
• The company's existing stockholders will experience dilution as a result of the issuance of shares to Helena.
• The company may not be able to maintain a listing of its common stock on NYSE American.
• The company's chairman has significant control over key decision-making due to his control of a majority of the voting stock.

Future Outlook

The company intends to use the net proceeds obtained under the ELOC Agreement to fund Phase 1 and Phase 2 clinical trials of its product candidates, including ENV 105 and preclinical product candidates including KROS 101, potential acquisition or in-licensing activities, and working capital and general corporate purposes.

Management Comments

• Dr. Yu is committed to advancing Kairos' pipeline to tackle the most unmet needs in cancer: resistance to cancer therapeutics and the suppressed immune response in cancer.

Industry Context

Kairos Pharma is operating in the competitive biopharmaceutical industry, focusing on cancer therapeutics. The company is developing novel drugs targeting drug resistance and immune suppression, which are significant challenges in cancer treatment. The company's strategy involves leveraging academic research and clinical connections with industry collaborations.

Comparison to Industry Standards

• The document mentions competitors such as Pfizer and AstraZeneca, which are large pharmaceutical companies with established cancer therapies.
• Kairos is pursuing a strategy of developing companion biomarkers, which is becoming increasingly common in the pharmaceutical industry to improve patient selection and treatment outcomes.
• The company's focus on addressing drug resistance and immune suppression aligns with current trends in cancer research and drug development.

Stakeholder Impact

• Shareholders may experience dilution and potential market price volatility.
• The company's ability to fund clinical trials and develop new therapies could benefit patients.
• Employees may be affected by the company's financial performance and ability to execute its business plan.

Next Steps

• Continue Phase 1 and Phase 2 clinical trials of product candidates, including ENV 105.
• Advance preclinical product candidates including KROS 101.
• Pursue potential acquisition or in-licensing activities.
• Utilize proceeds for working capital and general corporate purposes.

Key Dates

Keywords

ELOC, equity line of credit, Helena Global Investment Opportunities, common stock, resale, PIPE offering, clinical trials, Kairos Pharma, financing, dilution